Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids bind and activate nuclear receptors that translocate to the nucleus and interact with glucocorticoid response elements on DNA. This interaction inhibits transcription of proinflammatory cytokines such as TNF and inflammatory mediators including NF-κB and phospholipase A2, effectively reducing inflammation in Crohn's disease patients.

Common glucocorticoids include prednisone, methylprednisolone, hydrocortisone, and budesonide. Prednisone is usually administered orally, while severe cases may require intravenous methylprednisolone. Hydrocortisone can be delivered via enemas or suppositories for localized relief in the rectum and sigmoid colon. Each route targets specific inflammation sites.

Budesonide is an enteric-release formulation that minimizes first-pass hepatic metabolism, resulting in low systemic bioavailability and fewer side effects than conventional glucocorticoids. This targeted delivery to the ileocecal region effectively treats inflammation while reducing systemic adverse effects associated with prolonged glucocorticoid use.

Prolonged glucocorticoid use can cause osteoporosis, arrhythmia, anxiety, gastritis, skin thinning, cardiovascular events, and psychiatric disturbances. Due to these significant side effects, prolonged glucocorticoid therapy is discouraged, and alternative treatment approaches such as drugs for treatment of Crohn's disease in IBD using immunomodulatory agents may be considered for long-term management.

Different routes target specific areas of inflammation. Prednisone is given orally for systemic effect, methylprednisolone intravenously for severe cases, and hydrocortisone via enemas or suppositories for localized rectal and sigmoid colon inflammation. Budesonide's enteric-release formulation specifically targets the ileocecal region while minimizing systemic absorption.

Glucocorticoids inhibit production of inflammatory cytokines including tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. They also reduce expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2), and NF-κB.

Budesonide exhibits high first-pass hepatic metabolism, resulting in low systemic bioavailability compared to prednisone and methylprednisolone. This metabolic difference reduces systemic side effects, though its efficacy in achieving clinical remission may be slightly lower than prednisolone for some patients with Crohn's disease.